Director, Regulatory Affairs - Global Labeling
Gilead SciencesFull Time
Expert & Leadership (9+ years)
PTC Therapeutics is a global commercial biopharmaceutical company. For over 25 years our team has been deeply committed to a unified purpose: Extending life’s moments for children and adults living with a rare disease.
At PTC, we cultivate an inclusive culture where everyone feels valued, respected, and empowered. We welcome candidates from all backgrounds to join our team, fostering a strong sense of belonging.
Visit our website to learn more about our company and culture! Site: www.ptcbio.com
The Senior Manager, Global Clinical Regulatory Lead, is responsible for providing strategic and operational direction for the planning, management, support and execution of regulatory activities for PTC drug products (clinical and commercial) within the US as applicable. This role includes responsibility for support of global clinical trials, regional registrations and life cycle management regulatory activities. This individual supports the Global Regulatory Lead on their assigned products.
This position collaborates with others in the Regulatory Affairs Strategy team, Regulatory Sub teams, and potential cross-functional teams on assigned projects.
The role is responsible for overseeing the IND submission in the US, as well as for clinical trials applications for the rest of world. Additionally, this role supports the GRL to ensure that regional regulatory strategies are executed in compliance with current, applicable regulations and standards.
This position works cross-functionally and serves as a liaison between Global Regulatory Affairs team members, other PTC departments, external service providers and contract manufacturers.
The Senior Manager, Regulatory Affairs US ensures adherence to relevant regulatory requirements and company Standard Operating Procedures (SOPs) as appropriate.
Develops therapies for CNS disorders
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.